Analyst Consensus ?
ConsensusBuy34 ratings
Bullish2573.5%
Neutral823.5%
Bearish13.0%
International Flavors & Fragrances Inc. · IFF · FY2025 Q1 · Calendar Q2 2025
IFF pairs broad-based growth with disciplined reinvestment, but risks remain
The call supports a constructive but conditional view: broad-based segment momentum, productivity work and targeted reinvestment can support the business, while tariff exposure, Food Ingredients weakness and leverage execution require monitoring.
Reported After market closeNYSEBasic Materials
$22.52B market cap
70quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $1.08
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $2.82B
Revenue surprise
—
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-7.1%
Event window
SPY move
+0.4%
Same window
Abnormal move
-7.5%
Stock minus SPY
Volume
2.1×
Versus trailing sessions
Subsequent drift
+3.9%
Up to 20 sessions
IFFSPY benchmark
Ask FN2 about IFF FY2025 Q1
Transcript, numbers and history already loaded
What drove IFF's -7.1% move after FY2025 Q1 earnings?What changed in IFF's guidance and outlook in FY2025 Q1?Give me the bull and bear case for IFF after FY2025 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The supplied analysis highlights the early completion of the Pharma Solutions divestiture, the launch of the Alpha Bio joint venture with Kemira, and quantified tariff exposure alongside maintained full-year guidance.
Guidance delta
Management maintained full-year revenue and adjusted EBITDA guidance despite macroeconomic and tariff uncertainty.
Key takeaways
- Management described broad-based momentum in Taste, Pharma Solutions, Scent and Health & Biosciences.
- The Pharma Solutions divestiture was completed ahead of schedule, supporting balance-sheet progress.
- Management plans continued investment in R&D, capital spending and the Alpha Bio joint venture.
- Productivity, mix improvement and cost mitigation remain central to the margin outlook.
- Food Ingredients protein weakness and tariff exposure remain important counterweights to the growth narrative.
Management priorities
- Advance the Alpha Bio joint venture and its Finland capacity
- Invest in R&D, digital transformation and productivity
- Maintain capital spending to support core growth segments
- Complete the debt tender offer and reduce leverage
Follow IFF with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$88.2Previous close
$67Low
$99.16Average
$170High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 14, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Citigroup | Buy | Buy | Maintain | Oct 7, 2026 |
| Argus Research | Buy | Buy | Maintain | Oct 7, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 7, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 6, 2026 |
| Benchmark | Buy | Buy | Maintain | Aug 6, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 1, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | May 7, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | May 7, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Feb 17, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Feb 13, 2026 |
| B of A Securities | Buy | Buy | Maintain | Oct 14, 2025 |
| Wolfe Research | Peer Perform | Underperform | Upgrade | Sep 8, 2025 |
| Tigress Financial | Buy | Buy | Maintain | Aug 26, 2025 |
| Baird | Outperform | Outperform | Maintain | May 8, 2025 |
| Stifel | Buy | Buy | Maintain | Apr 10, 2025 |
| Vertical Research | Buy | Hold | Upgrade | Nov 7, 2024 |
| Deutsche Bank | Buy | Buy | Maintain | Mar 20, 2024 |
| Jefferies | Buy | Hold | Upgrade | Jan 12, 2024 |
| Goldman Sachs | Neutral | Neutral | Maintain | Aug 10, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 8, 2023 |
| Societe Generale | Buy | Buy | Maintain | Nov 9, 2022 |
| Berenberg | Hold | Buy | Downgrade | Aug 24, 2022 |
| Exane BNP Paribas | Neutral | Underperform | Upgrade | Jan 12, 2021 |
| Stephens & Co. | Overweight | Overweight | Maintain | Jul 10, 2020 |
| CFRA | Buy | Buy | Maintain | May 13, 2020 |
| Stifel Nicolaus | Hold | Hold | Maintain | Dec 16, 2019 |
| Citi | Buy | Neutral | Upgrade | Nov 22, 2019 |
| KeyBanc | Overweight | Overweight | Maintain | Aug 8, 2019 |
| Raymond James | Underperform | Market Perform | Downgrade | Nov 16, 2018 |
| Argus | Hold | Buy | Downgrade | Jun 8, 2018 |
| Evercore ISI Group | Outperform | In Line | Upgrade | Jan 17, 2018 |
| Gabelli & Co. | Hold | Buy | Downgrade | Aug 10, 2016 |
| Edward Jones | Buy | Buy | Maintain | Oct 1, 2015 |
| Janney Capital | Buy | Buy | Maintain | Nov 25, 2013 |
Named analyst price targets
Upside is calculated against the persisted previous close $88.2. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Argus Research | Analyst unavailable | $95 | $84.2 | +7.7% | Oct 7, 2026 |
| Barclays | Analyst unavailable | $96 | $84.55 | +8.8% | Aug 7, 2026 |
| Robert W. Baird | Ghansham Panjabi | $100 | $85.61 | +13.4% | Aug 6, 2026 |
| UBS | Joshua Spector | $91 | $85.92 | +3.2% | Aug 6, 2026 |
| Oppenheimer | Analyst unavailable | $95 | $85.87 | +7.7% | Aug 6, 2026 |
| Vertical Research | Analyst unavailable | $93 | $85.63 | +5.4% | Aug 6, 2026 |
| Morgan Stanley | Analyst unavailable | $95 | $80.02 | +7.7% | Jul 1, 2026 |
| Oppenheimer | Analyst unavailable | $90 | $82.93 | +2.0% | May 7, 2026 |
| Barclays | Lauren Lieberman | $90 | $82.93 | +2.0% | May 7, 2026 |
| Barclays | Lauren Lieberman | $80 | $72.1 | -9.3% | Apr 14, 2026 |
| UBS | Joshua Spector | $75 | $73.13 | -15.0% | Apr 9, 2026 |
| Deutsche Bank | Analyst unavailable | $95 | $82.18 | +7.7% | Feb 17, 2026 |
| Mizuho Securities | Analyst unavailable | $92 | $83 | +4.3% | Feb 17, 2026 |
| Morgan Stanley | Lisa De Neve | $93 | $82.43 | +5.4% | Feb 13, 2026 |
| Robert W. Baird | Analyst unavailable | $90 | $82.44 | +2.0% | Feb 13, 2026 |
| UBS | Joshua Spector | $85 | $81.72 | -3.6% | Feb 13, 2026 |
| Oppenheimer | Analyst unavailable | $97 | $81.14 | +10.0% | Feb 13, 2026 |
| Barclays | Analyst unavailable | $91 | $81.5 | +3.2% | Feb 13, 2026 |
| Mizuho Securities | John Roberts | $85 | $76.97 | -3.6% | Feb 12, 2026 |
| Argus Research | Analyst unavailable | $80 | $72.78 | -9.3% | Jan 22, 2026 |
| Barclays | Lauren Lieberman | $78 | $70.78 | -11.6% | Jan 16, 2026 |
| UBS | Analyst unavailable | $71 | $69.23 | -19.5% | Jan 12, 2026 |
| UBS | Joshua Spector | $66 | $61.6 | -25.2% | Oct 6, 2025 |
| Mizuho Securities | Analyst unavailable | $75 | $61.51 | -15.0% | Oct 3, 2025 |
| Oppenheimer | Kristen Owen | $89 | $64.23 | +0.9% | Aug 7, 2025 |
| Barclays | Lauren Lieberman | $82 | $78.18 | -7.0% | Mar 27, 2025 |
| Argus Research | Alexandra Yates | $93 | $82.56 | +5.4% | Jan 7, 2025 |
| Morgan Stanley | Lisa De Neve | $110 | $91.21 | +24.7% | Nov 11, 2024 |
| Stifel Nicolaus | Mark Astachan | $121 | $103.88 | +37.2% | Oct 24, 2024 |
| Oppenheimer | Kristen Owen | $117 | $101.28 | +32.7% | Sep 11, 2024 |
| Mizuho Securities | John Roberts | $120 | $103.99 | +36.1% | Sep 3, 2024 |
| Stifel Nicolaus | Mark Astrachan | $115 | $95.67 | +30.4% | Jul 22, 2024 |
| UBS | Joshua Spector | $100 | $96.64 | +13.4% | Jul 9, 2024 |
| Jefferies | Laurence Alexander | $111 | $98.14 | +25.9% | Jun 24, 2024 |
| Oppenheimer | Kristen Owen | $116 | $97.9 | +31.5% | Jun 6, 2024 |
| Morgan Stanley | Lisa De Neve | $100 | $98.1 | +13.4% | May 21, 2024 |
| Jefferies | Laurence Alexander | $110 | $97.23 | +24.7% | May 8, 2024 |
| Mizuho Securities | John Roberts | $98 | $88.66 | +11.1% | May 7, 2024 |
| Barclays | Lauren Lieberman | $75 | $86.57 | -15.0% | Apr 12, 2024 |
| Wells Fargo | Michael Sison | $100 | $85.5 | +13.4% | Apr 4, 2024 |
| Deutsche Bank | David Begleiter | $100 | $83.92 | +13.4% | Mar 20, 2024 |
| Stifel Nicolaus | Mark Astachan | $85 | $83.05 | -3.6% | Mar 19, 2024 |
| Morgan Stanley | Lisa De Neve | $90 | $79.76 | +2.0% | Jan 22, 2024 |
| Jefferies | Laurence Alexander | $112 | $80.25 | +27.0% | Jan 12, 2024 |
| J.P. Morgan | Jeffrey Zekauskas | $67 | $80.97 | -24.0% | Jan 2, 2024 |
| Argus Research | John Eade | $85 | $75.67 | -3.6% | Nov 28, 2023 |
| Stifel Nicolaus | Mark Astrachan | $81 | $68.09 | -8.2% | Sep 18, 2023 |
| Stifel Nicolaus | Mark Astrachan | $160 | $133.19 | +81.4% | Jan 25, 2022 |
| Jefferies | Laurence Alexander | $180 | $144.97 | +104.1% | Jan 13, 2022 |
| Citigroup | PJ Juvekar | $147 | $136.21 | +66.7% | May 20, 2021 |
| Societe Generale | Thomas Swoboda | $170 | $138.69 | +92.7% | May 19, 2021 |
| Morgan Stanley | Lisa De Neve | $160 | $137.3 | +81.4% | Apr 12, 2021 |
Track every rating change on IFF the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationInternational Flavors & Fragrances Inc. (IFF), through its various subsidiaries, operates as a global developer and purveyor of active cosmetic and natural health ingredients. These vital components are incorporated into a wide array of consumer goods distributed across significant markets such as Europe, Africa, the Middle East, Greater Asia, North America, and Latin America. The company's activities are organized into four principal divisions: 1. Nourish: This segment focuses on natural and plant-derived specialty food ingredients, offering items like flavor compounds, savory solutions, and inclusions. It also provides natural food protection solutions, including antioxidants and anti-microbials, for use in beverages, confectionery, and dairy items. 2. Scent: The Scent division creates fragrance compounds, encompassing luxurious fine fragrances (perfumes and colognes) and everyday consumer fragrances.…
Historical context
All IFF earningsBasic Materials peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RPM RPM International Inc. | FY2027 Q1 · Calendar Q4 2026 | +1.5% | +3.2% | RPM posts record quarter, but input costs narrow the outlook |
Latest beats and misses
Who reports nextBeat on EPS
Missed on EPS
Get the IFF recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-04-22T00:02:47.536505+00:00
- Polygon adjusted daily market bars · 2026-10-14T10:10:43.455764+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-14T10:10:43.452964+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-14. For educational purposes only; not investment advice.